<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>BACKGROUND.</bold> Bacteriocins are peptides with antimicrobial efficacy produced by certain bacterial species. Probiotics indeed seem a promising method in the prevention of upper respiratory infections and our study would like to contribute to the results available in the literature, in order to underlie their true therapeutic potential role.<bold>MATERIAL AND METHODS.</bold> Our multicenter pilot prospective study investigates 366 patients from September 2015 to February 2016. All the patients were treated with a topical device made up of a suspension of two specific bacterial strains: Streptococcus salivarius 24SMB and Streptococcus oralis 89a to be administered as nasal spray. The nasal spray was administered twice daily for 7 days per month for three consecutive months. A questionnaire about the subjective efficacy of the therapy correlated to an improvement of symptoms was also collected from patients.<bold>RESULTS.</bold> After one year from the enrolment, a 70.07% reduction in the number of events compared with the number of expected episodes was observed.<bold>CONCLUSION.</bold> The aim of our data is to propose a new therapeutic approach to treat the recurrence of upper airway infection and to support an adequate therapy in all cases where the traditional antibiotic therapeutic protocol did not obtain completely efficient results in terms of recurrence.</abstract>

BACKGROUND. Bacteriocins are peptides with antimicrobial efficacy produced by certain bacterial species. Probiotics indeed seem a promising method in the prevention of upper respiratory infections and our study would like to contribute to the results available in the literature, in order to underlie their true therapeutic potential role.MATERIAL AND METHODS. Our multicenter pilot prospective study investigates 366 patients from September 2015 to February 2016. All the patients were treated with a topical device made up of a suspension of two specific bacterial strains: Streptococcus salivarius 24SMB and Streptococcus oralis 89a to be administered as nasal spray. The nasal spray was administered twice daily for 7 days per month for three consecutive months. A questionnaire about the subjective efficacy of the therapy correlated to an improvement of symptoms was also collected from patients.RESULTS. After one year from the enrolment, a 70.07% reduction in the number of events compared with the number of expected episodes was observed.CONCLUSION. The aim of our data is to propose a new therapeutic approach to treat the recurrence of upper airway infection and to support an adequate therapy in all cases where the traditional antibiotic therapeutic protocol did not obtain completely efficient results in terms of recurrence.

Multicentric study on the efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a in respiratory tract infections

Department of Medicine, surgery and neuroscience

Department of Ear, Nose and Throat, San Giovanni Hospital

Otorhinolaryngology Unit, “Guglielmo da Saliceto” Hospital

Otorhinolaryngology Unit, “V. Fazzi” Hospital, ASL Lecce

Department of Anesthesiology, Surgical and Emergency Sciences, Otolaryngology, Head and Neck Surgery Unit

Department Otorhinolaryngology, “Ascalesi” Hospital

Department of Otolaryngology, Civil Regional Hospital

Department of Otorhinolaryngology, P.A. Micone Hospital

Department of Otorhinolaryngology, Madonna del Soccorso Hospital

Romanian Journal of Rhinology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

BACKGROUND. Bacteriocins are peptides with antimicrobial efficacy produced by certain bacterial species. Probiotics indeed seem a promising method in the...

Multicentric study on the efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a in respiratory tract infections

Published Online: Mar 13, 2018

Page range: 33 - 37

Received: Oct 23, 2017

Accepted: Nov 29, 2017

DOI: https://doi.org/10.2478/rjr-2018-0004

Keywords
Streptococcus salivarius, Streptococcus oralis, pharyngitis, adenotonsillitis, acute otitis media

© 2018 Luisa Maria Bellussi et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Multicentric study on the efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a in respiratory tract infections

Published Online: Mar 13, 2018

Page range: 33 - 37

Received: Oct 23, 2017

Accepted: Nov 29, 2017

DOI: https://doi.org/10.2478/rjr-2018-0004

KeywordsStreptococcus salivarius, Streptococcus oralis, pharyngitis, adenotonsillitis, acute otitis media

© 2018 Luisa Maria Bellussi et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Keywords
Streptococcus salivarius, Streptococcus oralis, pharyngitis, adenotonsillitis, acute otitis media